Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cytek Biosciences Inc (NQ: CTKB )

5.110 +0.160 (+3.23%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cytek Biosciences Inc

< Previous 1 2 3 4 Next >
Sale of Flow Cytometry and Imaging Business From DiaSorin to Cytek® Biosciences Completed
From Cytek Biosciences, Inc.
Via GlobeNewswire
Why Top Ships Are Trading Lower By 45%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Amesite Inc. (NASDAQ: AMST) shares jumped 123% to $0.6284 after the company announced GPT-3 powered functionality to its AI toolkit for customers and users. 
Via Benzinga
Cytek Biosciences Acquires Flow Cytometry & Imaging Business From DiaSorin
Via Benzinga
Cytek Biosciences Earnings Perspective: Return On Capital Employed
Via Benzinga
Recap: Cytek Biosciences Q2 Earnings
  Cytek Biosciences (NASDAQ:CTKB) reported its Q2 earnings results on Wednesday, August 10, 2022 at 04:03 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Cytek® Biosciences to Acquire Flow Cytometry and Imaging Business from DiaSorin
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek Biosciences to Report Fourth Quarter and Full Year 2022 Financial Results on February 28, 2023
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek® Biosciences Partners with Bio-Rad to Expand Reagent Portfolios
New Agreement Enhances High-Parameter Panels on Cytek Cell Analysis Systems 
From Cytek Biosciences, Inc.
Via GlobeNewswire
Earnings Preview: Cytek Biosciences
  Cytek Biosciences (NASDAQ:CTKB) is set to give its latest quarterly earnings report on Wednesday, 2022-08-10. Here's what investors need to know before the announcement. 
Via Benzinga
Cytek Biosciences to Participate in Upcoming Investor Conferences
From Cytek Biosciences, Inc.
Via GlobeNewswire
Oak Street Health, PriceSmart And Some Other Big Stocks Moving Higher In Tuesday's Pre-Market Session
U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
5 Most Cheapest Stocks In The Healthcare Sector: Bio-Techne, Mirati Therapeutics And More
The most oversold stocks in the healthcare sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
Cytek Biosciences to Participate in the Piper Sandler Healthcare Conference
From Cytek Biosciences, Inc.
Via GlobeNewswire
Where Cytek Biosciences Stands With Analysts
Cytek Biosciences (NASDAQ:CTKB) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Earnings Scheduled For May 11, 2022
Companies Reporting Before The Bell • Great Elm Capital (NASDAQ:GECC) is expected to report earnings for its first quarter. 
Via Benzinga
Cytek® Biosciences Introduces Cytek Cloud
New Digital Ecosystem Supports Full Spectrum Flow Cytometry Research – from Panel Design to Data Acquisition 
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek Biosciences Reports Third Quarter 2022 Financial Results
From Cytek Biosciences, Inc.
Via GlobeNewswire
Earnings Outlook For Cytek Biosciences
Cytek Biosciences (NASDAQ:CTKB) is set to give its latest quarterly earnings report on Wednesday, 2022-11-09. Here's what investors need to know before the announcement. Analysts estimate that Cytek... 
Via Benzinga
Cytek® Biosciences Names Chris Williams Chief Operating Officer
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek Biosciences to Report Third Quarter 2022 Financial Results on November 9, 2022
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek to Participate in the 31st Annual Credit Suisse Healthcare Conference
From Cytek Biosciences, Inc.
Via GlobeNewswire
Pinterest, Perion Network And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
U.S. stock futures traded lower this morning. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
Piper Sandler Maintains Overweight Rating for Cytek Biosciences: Here's What You Need To Know
  Piper Sandler has decided to maintain its Overweight rating of Cytek Biosciences (NASDAQ:CTKB) and raise its price target from $12.00 to $16.00. Shares of Cytek Biosciences are trading down 0.21%... 
Via Benzinga
Analyst Ratings for Cytek Biosciences
  Over the past 3 months, 4 analysts have published their opinion on Cytek Biosciences (NASDAQ:CTKB) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
74 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Analyst Ratings for Cytek Biosciences
Over the past 3 months, 4 analysts have published their opinion on Cytek Biosciences (NASDAQ:CTKB) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding... 
Via Benzinga
Goldman Sachs Maintains Buy Rating for Cytek Biosciences: Here's What You Need To Know
Goldman Sachs has decided to maintain its Buy rating of Cytek Biosciences (NASDAQ:CTKB) and lower its price target from $14.00 to $12.00. Shares of Cytek Biosciences are trading up 10.93% over the last... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 112 stocks made new 52-week lows. Noteworthy Highlights From Today's 52-Week Lows: Stanley Black & Decker (NYSE:SWK) was the largest firm by market... 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 63 companies set new 52-week lows. Noteworthy Mentions In Today's 52-Week Lows: The largest company by market cap to hit a new 52-week low was... 
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.